2025-10-04
Advanced Age and Neurotrauma Diminish Glutathione and Impair Antioxidant
Defense after Spinal Cord Injury; PY2022; USA (美國); IR95 Glutathione, 教材
Advanced Age and Neurotrauma Diminish Glutathione and Impair Antioxidant
Defense after Spinal Cord Injury
高齡與神經性創傷在脊髓損傷後會降低穀胱甘肽含量並削弱抗氧化防禦機制
Source or References (資訊來源或是參考的資訊):
https://pubmed.ncbi.nlm.nih.gov/35373589/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
2025年10月4日 星期六
Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines; PY2015; USA (美國);_IR94_
2025-10-04
Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines
Source or References (資訊來源或是參考的資訊):
https://pmc.ncbi.nlm.nih.gov/articles/PMC4425716/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines
Source or References (資訊來源或是參考的資訊):
https://pmc.ncbi.nlm.nih.gov/articles/PMC4425716/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients; PY2007; IR94
2025-10-04
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients; PY2007; IR94
Source or References (資訊來源或是參考的資訊):
https://pmc.ncbi.nlm.nih.gov/articles/PMC2039853/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients; PY2007; IR94
Source or References (資訊來源或是參考的資訊):
https://pmc.ncbi.nlm.nih.gov/articles/PMC2039853/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
Pharmacokinetics of intravenous ATP in cancer patients; PY2000_IR94, Glutathione
Pharmacokinetics
of intravenous ATP in cancer patients; PY2000_IR94, Glutathione
--- - - --- - - ---
2025-10-04
Pharmacokinetics of intravenous ATP in cancer patients; PY2000_IR94, Glutathione
Source or References (資訊來源或是參考的資訊):
https://pubmed.ncbi.nlm.nih.gov/10853877/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
- - - - - - - -
Clinical Trial Eur J Clin Pharmacol
. 2000 Apr;56(1):49-55. doi: 10.1007/s002280050719.
Pharmacokinetics of intravenous ATP in cancer patients
Pharmacokinetics of intravenous ATP in cancer patients
Pharmacokinetics of intravenous ATP in cancer patients
H J Agteresch 1, P C Dagnelie, T Rietveld, J W van den Berg, A H Danser, J H Wilson
Affiliations collapse
Affiliation
1Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, The Netherlands.
PMID: 10853877 DOI: 10.1007/s002280050719
Abstract
Objective: To characterise the pharmacokinetics of adenosine 5'-triphosphate (ATP) in patients with lung cancer after i.v. administration of different ATP dosages.
Methods: Twenty-eight patients received a total of 176 i.v. ATP courses of 30 h. Fifty-two infusions were given as low-dose infusions of 25-40 microg kg(-1) min(-1), 47 as middle-dose infusions of 45-60 microg kg(-1) min(-1) and 77 as high-dose infusions of 65-75 microg kg(-1) min(-1) ATP. Kinetic data of ATP concentrations in erythrocytes were available from 124 ATP courses. Results are expressed as mean +/- SEM.
Results: Most ATP courses in cancer patients were without side effects (64%), and side effects occurring in the remaining courses were mild and transient, resolving within minutes after decreasing the infusion rate. Baseline ATP concentration in erythrocytes was 1,554 +/- 51 micromol l(-1). ATP plateau levels at 24 h were significantly increased by 53 +/- 3, 56 +/- 3 and 69 +/- 2% after low-dose, middle-dose and high-dose ATP infusions, respectively. At the same time, significant increases in plasma uric acid concentrations were observed: 0.06 +/- 0.01, 0.11 +/- 0.01 and 0.16 +/- 0.01 mmol l(-1), respectively. The mean half-time for disappearance of ATP from erythrocytes, measured in five patients, was 5.9 +/- 0.5 h.
Conclusions: During constant i.v. infusion of ATP in lung cancer patients, ATP is taken up by erythrocytes and reaches dose-dependent plateau levels 50-70% above basal concentrations at approximately 24 h.
PubMed Disclaimer
Similar articles
Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines.
Rapaport E, Salikhova A, Abraham EH.
Purinergic Signal. 2015 Jun;11(2):251-62. doi: 10.1007/s11302-015-9450-y. Epub 2015 Apr 29.
PMID: 25917594Free PMC article.Clinical Trial.
Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer.
Agteresch HJ, Leij-Halfwerk S, Van Den Berg JW, Hordijk-Luijk CH, Wilson JH, Dagnelie PC.
Clin Sci (Lond). 2000 Jun;98(6):689-95.
PMID: 10814606Clinical Trial.
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients.
Beijer S, Gielisse EA, Hupperets PS, van den Borne BE, van den Beuken-van Everdingen M, Nijziel MR, van Henten AM, Dagnelie PC.
Invest New Drugs. 2007 Dec;25(6):571-9. doi: 10.1007/s10637-007-9076-1. Epub 2007 Sep 5.
PMID: 17786387Free PMC article.Clinical Trial.
Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study.
Leij-Halfwerk S, Agteresch HJ, Sijens PE, Dagnelie PC.
Hepatology. 2002 Feb;35(2):421-4. doi: 10.1053/jhep.2002.31318.
PMID: 11826418
[Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V.
Onkologie. 2006 Mar;29 Suppl 1:1-28. doi: 10.1159/000091889. Epub 2006 Mar 3.
PMID: 16534241Review.German.
See all similar articles
Cited by
Intravenous administration of adenosine triphosphate combined with escitalopram in major depressive disorder: protocol for a randomised, double-blind, placebo-controlled trial.
Xin Q, Wei H, Paudel D, Hu N, Zhao Y, Feng Y, Luo X, Su M, Xue X, Huang H, Lv Z, Tang C, Zhao Y, Tan M, Luo X, Yang Y, Liu Q, Huang M, Cheng Y, Gao T, Zhang B.
BMJ Open. 2025 Aug 28;15(8):e098281. doi: 10.1136/bmjopen-2024-098281.
PMID: 40876882Free PMC article.
Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
Chen Y, Cao X, Zang W, Tan S, Ou CQ, Shen X, Gao T, Zhao L.
Trials. 2019 Jan 9;20(1):34. doi: 10.1186/s13063-018-3115-4.
PMID: 30626424Free PMC article.
Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial.
Beijer S, van Rossum E, Hupperets PS, Spreeuwenberg C, van den Beuken M, Winkens RA, Ars L, van den Borne BE, de Graeff A, Dagnelie PC.
BMC Public Health. 2007 Jan 8;7:4. doi: 10.1186/1471-2458-7-4.
PMID: 17210069Free PMC article.
The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART.
Wagner MC.
Curr HIV Res. 2011 Jun;9(4):209-22. doi: 10.2174/157016211796320289.
PMID: 21675943Free PMC article.
The pathophysiology of cancer-related fatigue: current controversies.
O'Higgins CM, Brady B, O'Connor B, Walsh D, Reilly RB.
Support Care Cancer. 2018 Oct;26(10):3353-3364. doi: 10.1007/s00520-018-4318-7. Epub 2018 Jun 30.
PMID: 29961146Review.
See all "Cited by" articles
- - - - -- -- - -
--- --- - - --- ---
--- - - --- - - ---
2025-10-04
Pharmacokinetics of intravenous ATP in cancer patients; PY2000_IR94, Glutathione
Source or References (資訊來源或是參考的資訊):
https://pubmed.ncbi.nlm.nih.gov/10853877/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
- - - - - - - -
Clinical Trial Eur J Clin Pharmacol
. 2000 Apr;56(1):49-55. doi: 10.1007/s002280050719.
Pharmacokinetics of intravenous ATP in cancer patients
Pharmacokinetics of intravenous ATP in cancer patients
Pharmacokinetics of intravenous ATP in cancer patients
H J Agteresch 1, P C Dagnelie, T Rietveld, J W van den Berg, A H Danser, J H Wilson
Affiliations collapse
Affiliation
1Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, The Netherlands.
PMID: 10853877 DOI: 10.1007/s002280050719
Abstract
Objective: To characterise the pharmacokinetics of adenosine 5'-triphosphate (ATP) in patients with lung cancer after i.v. administration of different ATP dosages.
Methods: Twenty-eight patients received a total of 176 i.v. ATP courses of 30 h. Fifty-two infusions were given as low-dose infusions of 25-40 microg kg(-1) min(-1), 47 as middle-dose infusions of 45-60 microg kg(-1) min(-1) and 77 as high-dose infusions of 65-75 microg kg(-1) min(-1) ATP. Kinetic data of ATP concentrations in erythrocytes were available from 124 ATP courses. Results are expressed as mean +/- SEM.
Results: Most ATP courses in cancer patients were without side effects (64%), and side effects occurring in the remaining courses were mild and transient, resolving within minutes after decreasing the infusion rate. Baseline ATP concentration in erythrocytes was 1,554 +/- 51 micromol l(-1). ATP plateau levels at 24 h were significantly increased by 53 +/- 3, 56 +/- 3 and 69 +/- 2% after low-dose, middle-dose and high-dose ATP infusions, respectively. At the same time, significant increases in plasma uric acid concentrations were observed: 0.06 +/- 0.01, 0.11 +/- 0.01 and 0.16 +/- 0.01 mmol l(-1), respectively. The mean half-time for disappearance of ATP from erythrocytes, measured in five patients, was 5.9 +/- 0.5 h.
Conclusions: During constant i.v. infusion of ATP in lung cancer patients, ATP is taken up by erythrocytes and reaches dose-dependent plateau levels 50-70% above basal concentrations at approximately 24 h.
PubMed Disclaimer
Similar articles
Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines.
Rapaport E, Salikhova A, Abraham EH.
Purinergic Signal. 2015 Jun;11(2):251-62. doi: 10.1007/s11302-015-9450-y. Epub 2015 Apr 29.
PMID: 25917594Free PMC article.Clinical Trial.
Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer.
Agteresch HJ, Leij-Halfwerk S, Van Den Berg JW, Hordijk-Luijk CH, Wilson JH, Dagnelie PC.
Clin Sci (Lond). 2000 Jun;98(6):689-95.
PMID: 10814606Clinical Trial.
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients.
Beijer S, Gielisse EA, Hupperets PS, van den Borne BE, van den Beuken-van Everdingen M, Nijziel MR, van Henten AM, Dagnelie PC.
Invest New Drugs. 2007 Dec;25(6):571-9. doi: 10.1007/s10637-007-9076-1. Epub 2007 Sep 5.
PMID: 17786387Free PMC article.Clinical Trial.
Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study.
Leij-Halfwerk S, Agteresch HJ, Sijens PE, Dagnelie PC.
Hepatology. 2002 Feb;35(2):421-4. doi: 10.1053/jhep.2002.31318.
PMID: 11826418
[Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V.
Onkologie. 2006 Mar;29 Suppl 1:1-28. doi: 10.1159/000091889. Epub 2006 Mar 3.
PMID: 16534241Review.German.
See all similar articles
Cited by
Intravenous administration of adenosine triphosphate combined with escitalopram in major depressive disorder: protocol for a randomised, double-blind, placebo-controlled trial.
Xin Q, Wei H, Paudel D, Hu N, Zhao Y, Feng Y, Luo X, Su M, Xue X, Huang H, Lv Z, Tang C, Zhao Y, Tan M, Luo X, Yang Y, Liu Q, Huang M, Cheng Y, Gao T, Zhang B.
BMJ Open. 2025 Aug 28;15(8):e098281. doi: 10.1136/bmjopen-2024-098281.
PMID: 40876882Free PMC article.
Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
Chen Y, Cao X, Zang W, Tan S, Ou CQ, Shen X, Gao T, Zhao L.
Trials. 2019 Jan 9;20(1):34. doi: 10.1186/s13063-018-3115-4.
PMID: 30626424Free PMC article.
Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial.
Beijer S, van Rossum E, Hupperets PS, Spreeuwenberg C, van den Beuken M, Winkens RA, Ars L, van den Borne BE, de Graeff A, Dagnelie PC.
BMC Public Health. 2007 Jan 8;7:4. doi: 10.1186/1471-2458-7-4.
PMID: 17210069Free PMC article.
The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART.
Wagner MC.
Curr HIV Res. 2011 Jun;9(4):209-22. doi: 10.2174/157016211796320289.
PMID: 21675943Free PMC article.
The pathophysiology of cancer-related fatigue: current controversies.
O'Higgins CM, Brady B, O'Connor B, Walsh D, Reilly RB.
Support Care Cancer. 2018 Oct;26(10):3353-3364. doi: 10.1007/s00520-018-4318-7. Epub 2018 Jun 30.
PMID: 29961146Review.
See all "Cited by" articles
- - - - -- -- - -
--- --- - - --- ---
Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis (還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷) PY2023 IR95
Reduced
glutathione ameliorates acute kidney injury by inhibiting ferroptosis (還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷) PY2023 IR95
--- - - --- - - ---
2025-10-04
Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis (還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷)
Source or References (資訊來源或是參考的資訊):
https://pmc.ncbi.nlm.nih.gov/articles/PMC10206672/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
- - - - - - - -
Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis
還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷
Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis (還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷)
還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷 (Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis)
by inhibiting
透過抑制
by inhibiting (透過抑制)
透過抑制 (by inhibiting)
by inhibiting ferroptosis
透過抑制 鐵凋亡
by inhibiting ferroptosis (透過抑制 鐵凋亡)
透過抑制 鐵凋亡 (by inhibiting ferroptosis)
kidney injury
腎損傷
kidney injury (腎損傷)
腎損傷 (kidney injury)
acute kidney injury
急性腎損傷
acute kidney injury (急性腎損傷)
急性腎損傷 (acute kidney injury)
Ferroptosis (鐵凋亡)
- - - - -- -- - -
--- --- - - --- ---
--- - - --- - - ---
2025-10-04
Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis (還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷)
Source or References (資訊來源或是參考的資訊):
https://pmc.ncbi.nlm.nih.gov/articles/PMC10206672/
Info cited on 2025-10-04-WD6 (資訊引用於 中華民國114年西元2025年10月4日) by 湯偉晉 (WeiJin Tang)
#
- - - - - - - -
Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis
還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷
Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis (還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷)
還原型穀胱甘肽 透過抑制 鐵凋亡 來改善 急性腎損傷 (Reduced glutathione ameliorates acute kidney injury by inhibiting ferroptosis)
by inhibiting
透過抑制
by inhibiting (透過抑制)
透過抑制 (by inhibiting)
by inhibiting ferroptosis
透過抑制 鐵凋亡
by inhibiting ferroptosis (透過抑制 鐵凋亡)
透過抑制 鐵凋亡 (by inhibiting ferroptosis)
kidney injury
腎損傷
kidney injury (腎損傷)
腎損傷 (kidney injury)
acute kidney injury
急性腎損傷
acute kidney injury (急性腎損傷)
急性腎損傷 (acute kidney injury)
Ferroptosis (鐵凋亡)
- - - - -- -- - -
--- --- - - --- ---
訂閱：
文章 (Atom)